AFT Pharmaceuticals (ASX:AFP) has seen its price jump +10% just shy of $3/sh on Thursday morning as the company reveals record revenues of $115 million in its interim FY26 report, a record for the company and the tenth consecutive quarter of growth.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This content has been prepared as part of a partnership with AFT Pharma Ltd and is intended for informational purposes only.
Profits after tax came in just south of $3 million while operating profit eyed $5 million as the company moved on from previous years of losses, driven in part by the company’s ongoing global expansion. The market appears to like that AFT remains on track to realise its $300 million target for FY27.
Australia remains the main cash-maker for the company, with revenues up +31% vs pcp from $50 million to $66.5 million; operating profits for the region were nearly $10M. Compare this to NZ revenues up 8% at $28M; Asia region revenues up 70% to $7.5M (driven heavily by South Korea), and International revenues up 133% to $12.9M for which the company pointed to licensing income.
South Africa and the United Kingdom remain key jurisdictions of focus as part of the company’s ongoing global expansion, with the U.K. market in particular. In the background, the company is also developing an IV iron-infusion product; this has been licenced in China, and a number of entities have inked agreements, including one of China’s top five pharmaceutical companies, Grand Life Sciences Group.
For those playing at home, AFT Pharma owns the ‘Maxigesic’ brand of OTC painkillers in Australia, but also boasts an incredibly diverse brand portfolio, both bricks-and-mortar and online via Amazon and other services.
AFP last traded at $2.97/sh.
Join the discussion: See what HotCopper users are saying about AFT Pharma Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.